Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

References

• Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015;6:46
   PubMed Web of Science ®Google Scholar
• Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010;46(2):270-83
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Bertolotto C. Melanoma: From melanocyte to genetic alterations and clinical options. Scientifica 2013;2013:635203
   PubMedGoogle Scholar
• Tas F. Metastatic behavior in melanoma: Timing, Pattern, Survival, and influencing factors. J Oncol 2012;2012:647684
   PubMedGoogle Scholar
• Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011;29(3):489-98
   PubMed Web of Science ®Google Scholar
• Teimouri F, Nikfar Sh, Abdollahi M. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res 2013;23(5):381-9
   PubMed Web of Science ®Google Scholar
• Menaa F. Latest approved therapies for metastatic melanoma: What comes next? J Skin Cancer 2013;2013:735282
   PubMedGoogle Scholar
• Scholtens A, Geukes Foppen MH, Blank CU, et al. Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression. Eur J Cancer 2015;51(5):642-52
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Weber JS. Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015;7(1):12-21
   PubMedGoogle Scholar
• Hoff H, Kolar P, Ambach A, et al. CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch. Mol Immunol 2010;47:1875-81
   PubMed Web of Science ®Google Scholar
• Johnson DB, Peng Ch, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 2015;7(2):97-106
   PubMed Web of Science ®Google Scholar
• Fernando J, Kumar S. Principles of cancer treatment by immunotherapy. Surgery 2015;33(3):117-21
   Google Scholar
• Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. J Oncol 2014;3:15-28
   Google Scholar
• Melero I, Grimaldi AM, Perez-Gracia1 JL, et al. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013;19(5):997-1008
   PubMed Web of Science ®Google Scholar
• Poole RM. Pembrolizumab: First global approval. Drugs 2014;74(16):1973-81
   PubMed Web of Science ®Google Scholar
• Riella LV, Paterson AM, Sharpe AH, et al. Role of the PD-1 Pathway in the immune response. Am J Transplan 2012;12(10):2575-87
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, et al. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011;84:409-21
   PubMedGoogle Scholar
• Allie SR, Zhang W, Fuse Sh, et al. Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol 2011;186(11
   Google Scholar
• Kefford R, Ribas A, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract no. 3005]. J Clin Oncol 2014;32:5s
   Web of Science ®Google Scholar
• Brahmer J, Drake C, Wollner I, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
   PubMed Web of Science ®Google Scholar
• Sosman J, Sznol M, McDermott DF, et al. Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with advanced melanoma (mel) [abstract]. Ann Oncol 2012;23:ix367
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33
   PubMed Web of Science ®Google Scholar
• Khalili JS, Liu S, Rodríguez-Cruz TG, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012;18(19):5329-40
   PubMed Web of Science ®Google Scholar
• Johnson DB, Lovly ChM, Flavin M, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 2015;3(3):288-95
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11(2):141-51
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5
   PubMed Web of Science ®Google Scholar
• Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2015;17(2):133-44
   Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591-603
   PubMed Web of Science ®Google Scholar
• Shin DS, bas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol 2015;33:23-35
   PubMed Web of Science ®Google Scholar
• A Phase 1b study of mdx-1106 in subjects with advanced or recurrent malignancies (MDX1106-03). Available from: https://clinicaltrials.gov/ct2/show/NCT00730639
   Google Scholar
• Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in patients with advanced solid tumors: clinical activity, safety, and molecular markers. Poster presentation European Society for Medical Oncology 2012
   Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, Durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32(10):1020-30
   PubMed Web of Science ®Google Scholar
• Sznol M, hen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19(5):1021-34
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• BMS-936558 (MDX-1106) In subjects with advanced/metastatic clear-cell renal cell carcinoma (RCC). Available from: https://clinicaltrials.gov/ct2/show/NCT01354431
   Google Scholar
• Phase I biomarker study (BMS-936558). Available from: https://clinicaltrials.gov/ct2/show/NCT01358721
   Google Scholar
• Eggermont A, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014;383:816-27
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372(21):2006-17
   PubMed Web of Science ®Google Scholar
• Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or –naïve melanoma. J Clin Oncol 2013;31(34):4311-18
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Ascierto PA, et al. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. J Transl Med 2015;13(Suppl 1):O6
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30
   PubMed Web of Science ®Google Scholar
• Weber JS, Minor DR, D’Angelo S, et al. A phase 3 randomized, open label study of nivolumab (anti-PD01; BMS 926558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Ann Oncol 2014;25:1-41
   Google Scholar
• Larkin J, Chiarion–Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373(1):23-34
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with pembrolizumab (anti–PD-1) in melanoma. N Engl J Med 2013;369:134-44
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody mk-3475 in 411 patients (PTS) with melanoma (MEL). J Clin Oncol 2014;32:5s
   Google Scholar
• Dummer R, Daud A, Puzanov I, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J Transl Med 2015;13(Suppl 1):O5
   PubMedGoogle Scholar
• Study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to ipilimumab in participants with advanced melanoma (MK-3475-006/KEYNOTE-006). Available from: https://clinicaltrials.gov/ct2/show/NCT01866319
   Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372(26):2521-32
   PubMed Web of Science ®Google Scholar
• Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 2014;87:381-9
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [abstract]. J Clin Oncol 2012;30
   Google Scholar
• Brahmer JR, Tykodi SS, Chow L, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Ribas A, Robert C, Daud A, et al. clinical efficacy and safety of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced melanoma. J Clin Oncol 2013;31
   Google Scholar
• Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015. [Epub ahead of print]
   Google Scholar
• Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Mol Immunol 2015. [Epub ahead of print]
   Google Scholar
• Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 2015;11(9):1307-26
   PubMed Web of Science ®Google Scholar
• Benson DMJr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286-94
   PubMed Web of Science ®Google Scholar
• Phase 3 Study of nivolumab or nivolumab plus ipilimumab versus ipilimumab alone in previously untreated advanced melanoma (CheckMate 067). Available from: https://clinicaltrials.gov/ct2/show/NCT01844505
   Google Scholar
• Study of nivolumab (BMS-936558) in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). Available from: https://clinicaltrials.gov/ct2/show/NCT01454102
   Google Scholar
• Multiple class I peptides & montanide ISA 51 VG w escalating doses of anti-PD-1 ab BMS936558. Available from: https://clinicaltrials.gov/ct2/show/NCT01176461
   Google Scholar
• A phase I trial of a vaccine combining multiple class I peptides and montanide ISA 51VG with escalating doses of anti-PD-1 antibody nivolumab or ipilimumab with nivolumab for patients with resected stages IIIC/IV melanoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01176474
   Google Scholar
• Nivolumab (BMS-936558; MDX-1106) in combination with sunitinib, pazopanib, or ipilimumab in subjects with metastatic renal cell carcinoma (RCC) (CheckMate 016). Available from: https://clinicaltrials.gov/ct2/show/NCT01472081
   Google Scholar
• A phase i study of an anti-KIR antibody in combination with an anti-PD1 antibody in patients with advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01714739
   Google Scholar
• Safety study of IL-21/Anti-PD-1 combination in the treatment of solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01629758
   Google Scholar
• Opdivo (nivolumab) injection prescribing information, Bristol-Myers Squibb Company. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf
   Google Scholar
• EYTRUDA® (pembrolizumab) for injection prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf
   Google Scholar
• Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 2014;32:5s
   Google Scholar